5 Years Experience in 33 Preterms and Newborns at High Risk of Perinatal HIV-1 Transmission: HIV-1 Negative after a Triple Antiretroviral Prophylaxis

2006 ◽  
Vol 210 (S 1) ◽  
Author(s):  
S Hien ◽  
B Buchholz ◽  
M Beichert ◽  
T Schaible
Keyword(s):  
High Risk ◽  
Perinatal Hiv ◽  
Antiretroviral Prophylaxis ◽  
Hiv 1

scholarly journals Safety and Experience With Combined Antiretroviral Prophylaxis in Newborn at High-risk of Perinatal HIV Infection, in a Cohort of Mother Living With HIV-infant Pairs

2021 ◽  
Vol 40 (12) ◽  
pp. 1096-1100
Author(s):  
Marta Illán Ramos ◽  
Beatriz Soto Sánchez ◽  
Diana Mazariegos Orellana ◽  
Luis Manuel Prieto Tato ◽  
Sara Guillén Martín ◽  
...  
Keyword(s):  
High Risk ◽  
Hiv Infection ◽  
Perinatal Hiv ◽  
Antiretroviral Prophylaxis ◽  
Living With Hiv

Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01LS in HIV-1-Exposed Newborn Infants

2021 ◽  
Author(s):  
Elizabeth J McFarland ◽  
Coleen K Cunningham ◽  
Petronella Muresan ◽  
Edmund V Capparelli ◽  
Charlotte Perlowski ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Half Life ◽  
Newborn Infants ◽  
Adjunct Treatment ◽  
Perinatal Hiv ◽  
Antiretroviral Prophylaxis ◽  
Terminal Half Life ◽  
Local Reactions ◽  
Long Acting ◽  
Hiv 1

Abstract Background Perinatal HIV-1 continues to occur due to barriers to effective antiretroviral prevention that might be mitigated by long-acting broadly neutralizing monoclonal antibodies (bNAbs). Methods Extended half-life bNAb, VRC01LS, was administered subcutaneously (SC) at 80 mg/dose after birth to HIV-1-exposed, non-breastfed (Cohort 1, n=10) and breastfed (Cohort 2, n=11) infants. Cohort 2 received a second dose (100mg) at 12 weeks. All received antiretroviral prophylaxis. VRC01LS levels were compared to VRC01 levels determined in a prior cohort. Results Local reactions (all Grade <2) occurred in 67% and 20% after Dose 1 and Dose 2, respectively. The weight-banded dose (mean 28.8 mg/kg) of VRC01LS administrated SC achieved a mean +SD plasma level of 222.3 + 71.6 mcg/mL by 24 hours and 44.0 + 11.6 mcg/mL at week 12, prior to Dose 2. The pre-established target of > 50 mcg/mL was attained in 95% and 32% at week 8 and 12, respectively. The terminal half-life was 37-41 days. VRC01LS level after one dose was significantly greater (p=<0.002) than after a VRC01 dose (20mg/kg). No infants acquired HIV-1. Conclusions VRC01LS was well tolerated with pharmacokinetics that support further studies of more potent long-acting bNAbs as adjunct treatment with ARVs to prevent infant HIV-1 transmission.

scholarly journals Prospective study of correlates of vaginal Lactobacillus colonisation among high-risk HIV-1 seronegative women

2009 ◽  
Vol 85 (5) ◽  
pp. 348-353 ◽  
Author(s):  
J M Baeten ◽  
W M Hassan ◽  
V Chohan ◽  
B A Richardson ◽  
K Mandaliya ◽  
...  
Keyword(s):  
High Risk ◽  
Prospective Study ◽  
Vaginal Lactobacillus ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document